Will the tide turn for the wave of pharma layoffs?
Pharmaceutical Technology
OCTOBER 30, 2024
Pharmaceutical management expert Kenneth Getz shares insights on broader trends in the pharma sector influencing the recent wave of layoffs.
Wed.Oct 30, 2024
130 
A new biotech, built around protein design, springs from David Baker’s lab
Bio Pharma Dive
OCTOBER 30, 2024
Archon Biosciences, co-founded by the winner of the 2024 Nobel Prize in Chemistry, emerged from stealth Wednesday with $20 million in seed capital.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Biogen and Neomorph enter molecular glue degrader deal
Pharmaceutical Technology
OCTOBER 30, 2024
Biogen and Neomorph have partnered to discover and develop molecular glue degraders for treating Alzheimer’s and other rare conditions.
Biogen, Sage admit a defeat in major depression
Bio Pharma Dive
OCTOBER 30, 2024
The partners no longer intend to develop Zurzuvae for one of the most common forms of depression, citing the time and cost of running new studies that would satisfy the FDA.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
GSK to acquire Chimagen’s CMG1A46 for autoimmune disease
Pharmaceutical Technology
OCTOBER 30, 2024
GlaxoSmithKline (GSK) has entered an agreement to acquire Chimagen Biosciences’ CMG1A46 for $300m upfront.
Lilly shares fall as obesity drug sales miss forecasts
Bio Pharma Dive
OCTOBER 30, 2024
Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to the second quarter amid inventory decreases in the U.S.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
GSK vaccine sales sink on lower demand for RSV, shingles shots
Bio Pharma Dive
OCTOBER 30, 2024
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of its competing RSV shot.
How a patient helped shape a treatment for rare skin disorder
Pharmaceutical Technology
OCTOBER 30, 2024
Barman-Aksӧzen shared her experience of guiding treatment research for her own ultra rare disorder, erythropoietic protoporphyria (EPP).
Novo takes big step toward ending Ozempic, Wegovy shortages
Bio Pharma Dive
OCTOBER 30, 2024
All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned patients may still experience "variability" filling their prescriptions.
Investors put $115M into Axonis amid revived interest in brain drugs
Bio Pharma Dive
OCTOBER 30, 2024
The funding for Axonis, which is developing novel medicines for pain and epilepsy, reflects growing confidence in precision therapies for neurological diseases, one investor told BioPharma Dive.
Bladder cancer diagnoses to top 300,000 in major markets by 2033
Pharmaceutical Technology
OCTOBER 30, 2024
Bladder cancer is the ninth most common cancer globally, and the number of diagnosed incident cases is set to increase.
Biogen optimistic as new products gain traction
Bio Pharma Dive
OCTOBER 30, 2024
Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business, according to one analyst.
Roche to leverage Dyno Therapeutics tech for novel gene therapies in neuro disorders
Pharmaceutical Technology
OCTOBER 30, 2024
With the formation of a new strategic partnership, Dyno Therapeutics is responsible for the development of novel AAV capsids.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
October 30, 2024: In This Week’s PCT Grand Rounds, the CHI-RON Study of Adults With Congenital Heart Defects
Rethinking Clinical Trials
OCTOBER 30, 2024
Dr. Thomas Carton and Dr. Anitha John In this Friday’s PCT Grand Rounds, Thomas Carton of the Louisiana Public Health Institute and Anitha John of George Washington University and the Children’s National Hospital will present “Congenital Heart Initiative: Redefining Outcomes and Navigation to Adult Centered Care (CHI-RON) Study.” The Grand Rounds session will be held on Friday, November 1, 2024, at 1:00 pm eastern.
Pfizer boasts over 30% increase in Q3 revenues against previous year
Pharmaceutical Technology
OCTOBER 30, 2024
Amidst a share value slump and executive turmoil, Pfizer reported a robust quarter thanks in part to Covid-19 drug sales.
FDA Approves Jylamvo for Pediatric Patients, Expanding Methotrexate Options
XTalks
OCTOBER 30, 2024
Shorla Oncology recently received US Food and Drug Administration (FDA) approval to expand Jylamvo ’s (methotrexate) use for children with acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis. Jylamvo, an oral liquid methotrexate, can now treat pediatric patients with acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis.
Spero’s stock slides after antibiotic flops in Phase II trial
Pharmaceutical Technology
OCTOBER 30, 2024
The company has laid off 39% of its staff as it discontinued the development of SPR720 for non-tuberculous mycobacterial pulmonary disease.
GSK tries to steady the ship as Arexvy sales plummet in wake of CDC guidance changes
Fierce Pharma
OCTOBER 30, 2024
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the British drugmaker. For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales.
ARIA-E risk of Lilly’s Kisunla in Alzheimer’s reduced with modified dosing
Pharmaceutical Technology
OCTOBER 30, 2024
Lilly’s Alzheimer’s drug Kisunla was approved in the US, Japan, and the UK, among other countries.
Sage discontinues Zulresso, drops pair of pipeline prospects as it creeps toward 2026 cash cliff
Fierce Pharma
OCTOBER 30, 2024
Ever since the FDA rejected zuranolone in major depressive disorder last year, brai | In the wake of a recent round of layoffs, the company this week revealed that it’s discontinuing a commercial medicine and giving up hopes for a pair of pipeline prospects.
Novartis’ Scemblix gains FDA approval for leukaemia
Pharmaceutical Technology
OCTOBER 30, 2024
Novartis has received FDA accelerated approval for Scemblix (asciminib) to treat adults with newly diagnosed Ph+ CML-CP.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Lilly touts new Kisunla regimen that reduces side effects
pharmaphorum
OCTOBER 30, 2024
Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for drugs in its class.Simply shifting one vial of the anti-amyloid antibody from the first infusion to the third infusion of the titration phase of dosing – the period used to achieve therapeutic levels in the body – is enough to lower the incidence of a potentially serious side effect known as ARIA-E, accordi
IDWeek 2024: Kalihinol analogue shows promise as targeted antimalarial therapy
Pharmaceutical Technology
OCTOBER 30, 2024
The Kalihinol analogue is an innovative approach to malaria treatment, targeting the apicoplast to undermine P falciparum’s functions.
Novartis gets FDA okay for frontline use of Scemblix in CML
pharmaphorum
OCTOBER 30, 2024
Novartis says FDA approval for frontline use of its leukaemia drug Scemblix will boost the number of eligible patients four-fold, as it hunts blockbuster sales
Baxter exits China IV fluids market amid tough local competition, US shortage
Fierce Pharma
OCTOBER 30, 2024
Baxter International plans to exit China’s intravenous fluids market, multiple local media outlets report, citing a letter to distributors. | Baxter plans to exit China's IV fluids market as it faces tough local competition and as it redirects global IV supplies to the U.S. to cope with a post-hurricane shortage.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
AI and trusted data: The key to unlocking faster, more cost-effective drug discovery
pharmaphorum
OCTOBER 30, 2024
Discover how GenAI is leveraging AI technology to streamline R&D processes, ensuring trusted data and accelerating drug discovery timelines while reducing costs.
Amgen reaps Horizon buyout rewards in Q3 as it gears up for key biosim launches
Fierce Pharma
OCTOBER 30, 2024
It’s been about one year since Amgen closed its $27.8 billion Horizon Therapeutics buyout and brought the rare disease drug maker’s clutch of approved therapies under its fold. | In the third quarter, the company's overall sales grew 23% year over year and 8% excluding contributions from its Horizon Therapeutics buyout to $8.5 billion.
UK Chancellor pledges £22bn rise in day-to-day NHS spending
pharmaphorum
OCTOBER 30, 2024
The UK's first female Chancellor Rachel Reeves pumps billions into NHS in the first Labour budget in 14 years
Biogen boosts profit guidance despite modest quarter for Leqembi and multiple sclerosis downturn
Fierce Pharma
OCTOBER 30, 2024
Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. | All told, third-quarter U.S. Leqembi sales grew 33% over the prior quarter to $39 million, falling short of consensus estimates. But behind the scenes, there was a 40% uptick in the number of new prescribers writing prescriptions for Leqembi in the third quarter versus Q2, Alicia Alaimo, Biogen’s president and head of North America, said Wednesday.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content